Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is projected to have a strong financial future due to their innovative technology, platform potential, and promising pipeline, specifically agenT-797 for treatment of NSCLC and gastric cancer with 10% and 15% probability of success, respectively. However, risks include safety signals or lower-than-expected efficacy in clinical programs, potential commercial competition, regulatory concerns, and financing needs.

Bears say

MiNK Therapeutics is currently valued at $0.67 billion and has a Buy rating and a $35 price target based on a discounted cash flow analysis, with risks to price target achievement including safety concerns, lower-than-expected clinical efficacy, and commercial competition. Furthermore, updates on their IPF trial are expected later in 2026, which could potentially expand the company's development into end stage idiopathic pulmonary fibrosis, supported by promising preclinical data. However, the company faces de-listing risk if shares drop below $1 and may require additional financing, with a projected cash runway into 2027.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.